OncLive TV

Heather Wakelee, MD, an assistant professor at the Stanford University School of Medicine and member of the Stanford Cancer Institute, discusses the results of the AVAPERL trial.

Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the potential to target cyclin E in breast cancer.

Everett E. Vokes, MD, Giant of Cancer Care in the Head and Neck Cancer Category, John E. Ultmann Professor of Medicine and Radiation Oncology, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses HPV-related head and neck cancer

Edward Bradley, MD, from MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.

Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.

Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri, discusses the future of The Cancer Genome Atlas project.

Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses reducing neurotoxicity in small cell lung cancer patients.

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

Jennifer Woyach, MD, discusses peripheral lymphocytosis in patients with chronic lymphocytic leukemia after they take ibrutinib.

Harvey I. Pass, MD, from the NYU Langone Medical Center, discusses the challenges of treating patients with mesothelioma.

Alice Y. Ho, MD, discusses postmastectomy radiation therapy for patients with breast cancer who have undergone breastreconstructive surgery.

Andrew T. Parsa, MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for patients with recurrent glioblastoma multiforme.

Lynn M. Schuchter, MD, from the University of Pennsylvania, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.

Gail Eckhardt, MD, from the University of Colorado Denver and Health Sciences Center, discusses the future role of aflibercept for patients with metastatic colorectal cancer.

Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the treatment of older patients with acute myeloid leukemia (AML).

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Bonnie Addario, a lung cancer survivor and founder of the Bonnie J. Addario Lung Cancer Foundation (BJALCF), discusses support groups for patients with lung cancer.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the future of antibodies, including nivolumab, for the treatment of lung cancer.

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, believes this is an exciting time in the field of gastrointestinal cancers, as more tools become available to select the most effective treatment for each patient.

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the treatment of several cancers with bevacizumab.

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.

Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, comments on the recent developments in fighting cancer with the immune system.

Everett E. Vokes, MD, Giant of Cancer Care in Head and Neck from University of Chicago Medicine and Biological Sciences, discusses multimodality therapy for lung cancer.

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses integrating the irreversible pan-HER inhibitor afatinib into the treatment paradigm for patients with advanced non-small cell lung cancer.

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, on using a Ki67 assay for patients with breast cancer.

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

Tony S.K. Mok, BMSc, MD, FRCPC, from the Chinese University of Hong Kong, discusses different plasma testing approaches for patients with lung cancer.

Heather Wakelee, MD, from the Stanford University School of Medicine, describes two phase III trials that focused on the second-line nintedanib plus chemotherapy to treat patients with advanced non-small cell lung cancer.

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, gives an overview of the development of PI3K and mTOR inhibitors for the treatment of breast cancer.

Giorgio V. Scagliotti, MD, PhD, Head, from the University of Turin, Italy, discusses toxicities related to chemotherapy and surgery in patients with lung cancer.